New clinical trial on Longevity using MAF Triple
in Japan is underway.
Saisei Movies
CLINICAL STUDY MAF capsules efficacy in post-COVID syndrome treatment is started in KAZAKHSTAN
read more
CLINICAL STUDY MAF capsules efficacy in post-COVID syndrome treatment is started in KAZAKHSTAN
MedInc Ltd in Kazakhstan on the base of National Research Cardiac Surgery Center has started the implementation of prospective randomized open-label clinical trial: “Evaluation of immune modulator MAF capsules efficacy in a therapy of patients with post-COVID syndrome”. The study sponsored by the developer and manufacturer of the study product Saisei Pharma Co. Ltd, Japan.
The goal of the study is the evaluation of the safety and efficiency of a MAF capsules dietary supplement with anti-inflammatory immune response modulating function in combined treatment of the post-COVID syndrome. |
The trial started in February 2021 and targeted 200 patients with post-COVID syndrome, which will be randomized 1:1 in two groups:
Group 1: SOC (standard of care) + dietary supplement MAF capsules administration for 30 days.
Group 2: SOC
The study primary endpoints aim to evaluate the improvement within 30 days period after MAF capsules administration, where the clinical efficacy refers to an improvement of life quality according to Chalder Fatigue Scale and the “Postcovid syndrome” consequences and symptoms severity evaluation according to ISARIC questionnaire.
The study secondary endpoints included the evaluation of changes according to the Karnofsky Performance Scale and Numerical Rating Scale, and evaluation of the MAF capsules side effects.
The exploratory endpoints include effects on:
1. Lymphocyte count, T cells and its subpopulation count, and B cells count
2. The plasma level of IgG against SARS-CoV-2
read more
- Control group
- MAF Capsules (colostrum MAF) group
- M Capsules (whey MAF) group
- SOC (standard of care)
- SOC plus MAF Capsules (148 mg, 3 caps. TID for 14 days)
- SOC plus M Capsules (148 mg, 3 caps. TID for 14 days)
- No adverse events
- Decrease in the mortality rate
- Decrease in necessity and duration of supplemental oxygen
- Decrease in time to recovery
- Decrease in time until hospital discharge
- Preventing of respiratory failure
- Restoring the base-line decreased lymphocytes count
04-Mar-2021
28-Feb-2021
3rd Generation GcMAF was developed by Saisei Pharma for which we hold patents. There are fake GcMAF products sold online in Australia by a company which is registered in Hong Kong. Please be aware that 3rd Generation GcMAF products are only produced by Saisei Pharma. Any other products from other companies are fake products.
News
https://saisei-pharma.co.jp/maf-capsulestriple-en/
The hypothesis: Based on the aforementioned findings and on documented analogies between SARS-CoV-2 and HIV, we hypothesized that the reduced conversion activity of the Gc protein (human group-specific component (Gc)) into the macrophage activating factor (MAF) could have a key role in the dysregulate immune response induced by SARS-CoV-2, just like for HIV infected patients. If this hypothesis is correct, it might help to set a valid strategy of immunotherapy also based on an off-label use of GcMAF in critically ill COVID-19 patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513798/
Conclusion: According to the provided literature overview, we firmly believe that GcMAF deserves be tested as immune-therapeutic to increase macrophages functionality for earlier SARS-CoV-2 viral control, protection against COVID-19 progression by limiting epithelial damage, control local inflammation and prevent from the hyperinflammatory immune response. For this purpose, we planned a Phase-II interventional clinical trial evaluating the effectiveness and safety of Oral immunotherapy with Third Generation GcMAF in hospitalized patients with COVID-19 pneumonia (COral-MAF1 Trial) at the “Ospedale del Mare” Hospital, Naples, Italy.
Saisei Pharma plans clinical study of oral MAF in COVID-19 patients details were featured on some website.
Please check the below URL.
This time, the Saisei Mirai, has contracted official partnership with the Ukrainian National Cancer Center as partner hospitals.
Third
Generation GcMAF
Saisei Mirai
Saisei Pharma
Tokushima University
Developed by Saisei Mirai and Tokushima University in 2014.
MAF Series
• New patents pending production process
• Permitted as a food product in Japan
Second
Generation GcMAF
Developed by Saisei Mirai and the University of Tokushima in 2010.
・High concentration (1500 ng/0.5 ml, 1 dose)
・Significantly higher stability and macrophage activating activity
・Sterilization process using 0.22 μm filtration system
・New patented production process
First
Generation GcMAF
Tokushima University
Dr.Yamamoto
・Low stability at room temperature
・Chemically isolated (purified), sterilization process using 0.22 μm filtration system
・25-(OH) Vitamin D3 Affinity Column
・Affinity column has cross-contamination risk when used repeatedly; must be disposable
Cancer treatments / Skin rejuvenation treatments
Cancer treatments / Immunotherapy
Cancer treatments
Skin Beauty treatments
Saisei Mirai immunotherapy laboratory for the production of GcMAF,
Hyper T/NK cells, lymphocytes and other immunotherapies.
This site is for our patients and medical personnel.
Saisei Pharma is a bio venture company, developing Oral Colostrum GcMAF and researching ultrasonic sensitizers and electric field therapy.
Collaborative company
